Vigil Neuroscience IPO

1/7/2022

IPO

$98,000,000

We intend to use the net proceeds from this offering to advance the development of VGL101 for the treatment of ALSP and other rare leukoencephalopathies and leukodystrophies, including the initiation of clinical trials, clinical research outsourcing and drug manufacturing; for the continued research of our novel, small molecule program focusing on treatments for common neurodegenerative diseases that are linked to microglial dysfunction with genetically defined AD as the initial indication; for the continued research and development of our development programs, including the expansion of our modality agnostic product pipeline to include other microglial targets; and for working capital and other general corporate purposes.

Publicly-held

Biopharmaceutical

300 Technology Sq. 8th Floor
Cambridge, MA 02139
USA

We are discovering and developing novel therapeutics that take advantage of breakthroughs in basic science and human genetics of microglia. Vigil's drug pipeline consists of therapeutic candidates targeting critical microglial signaling pathways in which loss-of-function mutations cause life-threatening neurodegenerative diseases.